The inhibitor of mTOR obstructs the activation of T cells as well as mTORC1 and also lowers the production of IL-4 in SLE patients which has been seen to be very effective to treat SLE both in animal models as well as in patients. This evidence concerns the gene MTOR and systemic lupus erythematosus.